Pharma Mar, S.A. (PHM.MC)
EUR 76.95
(0.59%)
EUR 76.95
(0.59%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 27.03 Million EUR | -3.09% |
| 2022 | 27.89 Million EUR | -20.98% |
| 2021 | 35.3 Million EUR | -11.48% |
| 2020 | 39.88 Million EUR | -27.2% |
| 2019 | 54.78 Million EUR | -15.62% |
| 2018 | 64.92 Million EUR | -11.8% |
| 2017 | 73.6 Million EUR | 8.91% |
| 2016 | 67.58 Million EUR | 4.02% |
| 2015 | 64.97 Million EUR | 38.23% |
| 2014 | 47 Million EUR | -11.22% |
| 2013 | 52.94 Million EUR | -14.63% |
| 2012 | 62.01 Million EUR | -25.34% |
| 2011 | 83.06 Million EUR | -2.67% |
| 2010 | 85.33 Million EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | -100.0% |
| 2007 | 240 Thousand EUR | -32.58% |
| 2006 | 356 Thousand EUR | -96.11% |
| 2005 | 9.15 Million EUR | -47.08% |
| 2004 | 17.3 Million EUR | -63.25% |
| 2003 | 47.08 Million EUR | 107.82% |
| 2002 | 22.65 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 27.46 Million EUR | -4.25% |
| 2024 Q3 | 25.97 Million EUR | -0.19% |
| 2024 Q2 | 26.02 Million EUR | 0.55% |
| 2023 Q4 | 27.03 Million EUR | -6.21% |
| 2023 Q2 | 29.05 Million EUR | 1.84% |
| 2023 Q1 | 28.53 Million EUR | 2.28% |
| 2023 FY | 27.03 Million EUR | -3.09% |
| 2023 Q3 | 28.82 Million EUR | -0.81% |
| 2022 Q2 | 31.87 Million EUR | -4.44% |
| 2022 Q4 | 27.89 Million EUR | 2.24% |
| 2022 FY | 27.89 Million EUR | -20.98% |
| 2022 Q1 | 33.36 Million EUR | -5.5% |
| 2022 Q3 | 27.28 Million EUR | -14.41% |
| 2021 Q4 | 35.3 Million EUR | -7.94% |
| 2021 FY | 35.3 Million EUR | -11.48% |
| 2021 Q1 | 36.4 Million EUR | -8.73% |
| 2021 Q2 | 39.28 Million EUR | 7.91% |
| 2021 Q3 | 38.34 Million EUR | -2.38% |
| 2020 Q2 | 42.82 Million EUR | -4.99% |
| 2020 Q1 | 45.07 Million EUR | -17.72% |
| 2020 FY | 39.88 Million EUR | -27.2% |
| 2020 Q4 | 39.88 Million EUR | -4.24% |
| 2020 Q3 | 41.64 Million EUR | -2.75% |
| 2019 Q4 | 54.78 Million EUR | -6.9% |
| 2019 Q1 | 63.9 Million EUR | -1.56% |
| 2019 Q2 | 60.61 Million EUR | -5.15% |
| 2019 Q3 | 58.84 Million EUR | -2.93% |
| 2019 FY | 54.78 Million EUR | -15.62% |
| 2018 Q4 | 64.92 Million EUR | -0.97% |
| 2018 FY | 64.92 Million EUR | -11.8% |
| 2018 Q1 | 70.66 Million EUR | -4.0% |
| 2018 Q2 | 67.24 Million EUR | -4.84% |
| 2018 Q3 | 65.56 Million EUR | -2.5% |
| 2017 Q4 | 73.6 Million EUR | 2.69% |
| 2017 FY | 73.6 Million EUR | 8.91% |
| 2017 Q3 | 71.67 Million EUR | -3.02% |
| 2017 Q2 | 73.9 Million EUR | 12.11% |
| 2017 Q1 | 65.92 Million EUR | -2.46% |
| 2016 Q1 | 69.49 Million EUR | 6.96% |
| 2016 Q4 | 67.58 Million EUR | -5.63% |
| 2016 FY | 67.58 Million EUR | 4.02% |
| 2016 Q2 | 73.24 Million EUR | 5.4% |
| 2016 Q3 | 71.61 Million EUR | -2.23% |
| 2015 Q2 | 53.17 Million EUR | 22.52% |
| 2015 Q1 | 43.39 Million EUR | -7.67% |
| 2015 FY | 64.97 Million EUR | 38.23% |
| 2015 Q3 | 67.96 Million EUR | 27.83% |
| 2015 Q4 | 64.97 Million EUR | -4.41% |
| 2014 FY | 47 Million EUR | -11.22% |
| 2014 Q4 | 47 Million EUR | 4.22% |
| 2014 Q3 | 45.09 Million EUR | -3.15% |
| 2014 Q2 | 46.56 Million EUR | 9.36% |
| 2014 Q1 | 42.57 Million EUR | -19.57% |
| 2013 Q2 | 58.05 Million EUR | 0.62% |
| 2013 FY | 52.94 Million EUR | -14.63% |
| 2013 Q3 | 52.87 Million EUR | -8.91% |
| 2013 Q4 | 52.94 Million EUR | 0.12% |
| 2013 Q1 | 57.69 Million EUR | -6.97% |
| 2012 Q2 | 73.81 Million EUR | -7.23% |
| 2012 Q1 | 79.56 Million EUR | -4.21% |
| 2012 Q3 | 69.09 Million EUR | -6.39% |
| 2012 FY | 62.01 Million EUR | -25.34% |
| 2012 Q4 | 62.01 Million EUR | -10.25% |
| 2011 Q4 | 83.06 Million EUR | -4.47% |
| 2011 FY | 83.06 Million EUR | -2.67% |
| 2011 Q1 | 80.82 Million EUR | -5.29% |
| 2011 Q2 | 87.71 Million EUR | 8.53% |
| 2011 Q3 | 86.94 Million EUR | -0.88% |
| 2010 FY | 85.33 Million EUR | 0.0% |
| 2010 Q1 | 97.65 Million EUR | 0.0% |
| 2010 Q2 | 101.07 Million EUR | 3.5% |
| 2010 Q3 | 92.18 Million EUR | -8.79% |
| 2010 Q4 | 85.33 Million EUR | -7.43% |
| 2009 Q4 | - EUR | -100.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q1 | 85.74 Million EUR | 0.0% |
| 2009 Q3 | 92.89 Million EUR | 4.68% |
| 2009 Q2 | 88.73 Million EUR | 3.49% |
| 2008 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | -100.0% |
| 2007 FY | 240 Thousand EUR | -32.58% |
| 2006 FY | 356 Thousand EUR | -96.11% |
| 2005 FY | 9.15 Million EUR | -47.08% |
| 2004 FY | 17.3 Million EUR | -63.25% |
| 2003 FY | 47.08 Million EUR | 107.82% |
| 2002 FY | 22.65 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Atrys Health, S.A. | 162.72 Million EUR | 83.386% |
| Biotechnologies Assets SA | 5.15 Million EUR | -424.544% |
| Laboratorios Farmaceuticos Rovi, S.A. | 52.24 Million EUR | 48.249% |